Page 631 - Read Online

Peyvandi et al. J Cancer Metastasis Treat 2019;5:44 I http://dx.doi.org/10.20517/2394-4722.2019.16 Page 19 of 24

heterogeneity. Nature 2014;514:54-8.
82. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, et al. Circulating tumor cell clusters are oligoclonal precursors of breast
cancer metastasis. Cell 2014;158:1110-22.
83. Gkountela S, Castro-Giner F, Szczerba BM, Vetter M, Landin J, et al. Circulating Tumor Cell Clustering Shapes DNA Methylation to
Enable Metastasis Seeding. Cell 2019;176:98-112.e14.
84. Kmieciak M, Payne KK, Wang XY, Manjili MH. IFN-gamma Ralpha is a key determinant of CD8+ T cell-mediated tumor elimination or
tumor escape and relapse in FVB mouse. PLoS One 2013;8:e82544.
85. Demicheli R. Tumour dormancy: findings and hypotheses from clinical research on breast cancer. Semin Cancer Biol 2001;11:297-306.
86. Demicheli R, Retsky MW, Hrushesky WJ, Baum M. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer:
learning from failures. Nat Clin Pract Oncol 2007;4:699-710.
87. Endo H, Inoue M. Dormancy in cancer. Cancer Sci 2019;110:474-80.
88. Demicheli R, Biganzoli E, Boracchi P, Greco M, Retsky MW. Recurrence dynamics does not depend on the recurrence site. Breast Cancer
Res 2008;10:R83.
89. Dillekas H, Demicheli R, Ardoino I, Jensen SAH, Biganzoli E, et al. The recurrence pattern following delayed breast reconstruction
after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases. Breast Cancer Res Treat
2016;158:169-78.
90. Hanin L, Korosteleva O. Does extirpation of the primary breast tumor give boost to growth of metastases? Evidence revealed by
mathematical modeling. Math Biosci 2010;223:133-41.
91. Manjili MH. Tumor dormancy and relapse: from a natural byproduct of evolution to a disease state. Cancer Res 2017;77:2564-9.
92. Gelao L, Criscitiello C, Fumagalli L, Locatelli M, Manunta S, et al. Tumour dormancy and clinical implications in breast cancer.
Ecancermedicalscience 2013;7:320.
93. Rancoita PM, Valberg M, Demicheli R, Biganzoli E, Di Serio C. Tumor dormancy and frailty models: a novel approach. Biometrics
2017;73:260-70.
94. Klein CA, Holzel D. Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle
2006;5:1788-98.
95. Klauber-DeMore N, Van Zee KJ, Linkov I, Borgen PI, Gerald WL. Biological behavior of human breast cancer micrometastases. Clin
Cancer Res 2001;7:2434-9.
96. Naumov GN, MacDonald IC, Weinmeister PM, Kerkvliet N, Nadkarni KV, et al. Persistence of solitary mammary carcinoma cells in a
secondary site: a possible contributor to dormancy. Cancer Res 2002;62:2162-8.
97. Goodison S, Kawai K, Hihara J, Jiang P, Yang M, et al. Prolonged dormancy and site-specific growth potential of cancer cells
spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin Cancer Res
2003;9:3808-14.
98. Makita M, Sakai T, Ogiya A, Kitagawa D, Morizono H, et al. Optimal surveillance for postoperative metastasis in breast cancer patients.
Breast Cancer 2016;23:286-94.
99. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7:834-46.
100. Hensel JA, Flaig TW, Theodorescu D. Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol
2013;10:41-51.
101. Dittmer J. Mechanisms governing metastatic dormancy in breast cancer. Semin Cancer Biol 2017;44:72-82.
102. Paez D, Labonte MJ, Bohanes P, Zhang W, Benhanim L, et al. Cancer dormancy: a model of early dissemination and late cancer
recurrence. Clin Cancer Res 2012;18:645-53.
103. Giancotti FG. Mechanisms governing metastatic dormancy and reactivation. Cell 2013;155:750-64.
104. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to
p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001;12:863-79.
105. Osisami M, Keller ET. Mechanisms of Metastatic Tumor Dormancy. J Clin Med 2013;2:136-50.
106. Sosa MS, Parikh F, Maia AG, Estrada Y, Bosch A, et al. NR2F1 controls tumour cell dormancy via SOX9- and RARbeta-driven
quiescence programmes. Nat Commun 2015;6:6170.
107. Borgen E, Rypdal MC, Sosa MS, Renolen A, Schlichting E, et al. NR2F1 stratifies dormant disseminated tumor cells in breast cancer
patients. Breast Cancer Res 2018;20:120.
108. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by
p38(SAPK). Cancer Res 2003;63:1684-95.
109. Jo H, Jia Y, Subramanian KK, Hattori H, Luo HR. Cancer cell-derived clusterin modulates the phosphatidylinositol 3'-kinase-Akt pathway
through attenuation of insulin-like growth factor 1 during serum deprivation. Mol Cell Biol 2008;28:4285-99.
110. Vera-Ramirez L, Vodnala SK, Nini R, Hunter KW, Green JE. Autophagy promotes the survival of dormant breast cancer cells and
metastatic tumour recurrence. Nat Commun 2018;9:1944.
111. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian
cancer cells. J Clin Invest 2008;118:3917-29.
112. Balz LM, Bartkowiak K, Andreas A, Pantel K, Niggemann B, et al. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-gamma1
signalling in breast cancer cell migration and dissemination. J Pathol 2012;227:234-44.
113. Amaravadi RK. Autophagy-induced tumor dormancy in ovarian cancer. J Clin Invest 2008;118:3837-40.
114. Schewe DM, Aguirre-Ghiso JA. ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. Proc Natl Acad Sci
U S A 2008;105:10519-24.
115. Malladi S, Macalinao DG, Jin X, He L, Basnet H, et al. Metastatic latency and immune evasion through autocrine inhibition of WNT.
Cell 2016;165:45-60.